We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 3.66% | 21.25 | 20.50 | 22.00 | 21.25 | 20.50 | 20.50 | 1,088,151 | 10:14:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.55 | 55.37M |
TIDMAGL
Angle PLC
19 April 2016
London, UK, 19 April 2016
Edison issues research update on Angle
Angle has announced results from a metastatic breast cancer research study carried out by its KOL partner University of Southern California (USC) Norris Comprehensive Cancer Center. Headline data potentially prove that circulating cancer cells (CTCs) captured using Parsortix have the same biology compared to invasive tissue biopsy and can be used to guide the treatment. While this will have to be replicated in larger-scale trials, it represents a potential third clinical application, in which Parsortix can establish a new standard of care.
Angle will now focus on implementing a clinical trial in partnership with USC and other centres. When there is more clarity about commercialisation in terms of timelines and positioning, we will review our financial forecasts and the assumptions underlying our DCF-based valuation, which is unchanged at GBP95m or 161p/share for now.
Click here to view the full report
All reports published by Edison are available to download free of charge from its website: www.edisoninvestmentresearch.com
About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring that a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-investment-research --------- ---------------------------------------------------- Twitter www.twitter.com/Edison_Inv_Res --------- ---------------------------------------------------- YouTube www.youtube.com/edisonitv --------- ---------------------------------------------------- Google+ https://plus.google.com/105425025202328783163/posts --------- ----------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGMDMLMGVZM
(END) Dow Jones Newswires
April 19, 2016 07:43 ET (11:43 GMT)
1 Year Angle Chart |
1 Month Angle Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions